iScience · 2024 · 12 citations · 58 references
MedicineImmunologyOncologyCancer ImmunologyInflammationInnate ImmunityCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationMyeloid-derived Suppressor CellsTumor Immune MicroenvironmentImmune Checkpoint Inhibitor TherapyImmune Checkpoint ReceptorsMyeloid Cell TargetingMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell ModulationMyeloid-derived Suppressor Cell Signaling PathwaysMyeloid-derived Suppressor Cell-mediated SuppressionPhagocytic Activity
by exposing hematopoietic stem cells to tumor-derived factors. Engagement of CD47 with SIRPα on myeloid cells reduced their phagocytic capability, enhanced expression of immune checkpoints, increased reactive oxygen species production, and suppressed T cell proliferation. Perturbation of SIRPα signaling restored phagocytosis and antigen presentation by MDSCs, which was accompanied by renewed T cell activity and delayed tumor growth in multiple solid cancers. These data highlight that therapeutically targeting myeloid functions in combination with immune checkpoint inhibitors could enhance anti-tumor immunity.
58
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. Leach, Matthew F. Krummel, James P. Allison · Science · 1996 · 3.9K citations
Life Sciences, Immunology, Oncology +17
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations
Medicine, Oncology, Pharmacotherapy +13
Ravindra Majeti, Mark P. Chao, Ash A. Alizadeh et al. · Cell · 2009 · 1.7K citations
Medicine, Hematology, Oncology +14